Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LX102 in neovascular age-related macular degeneration (nAMD)
CTR20255009Phase 3Active
- Sponsor
- Langxin Qisheng
- Start
- Jan 2026
- Modality
- AAV Vectors → Viral Vectors → Gene Addition/Replacement → Gene Therapies
- Countries
- 1
01
Overview
A Phase 3 trial of LX102 in exudative macular degeneration, sponsored by Langxin Qisheng. Started Jan 2026; status: active.
02
Drugs
LX102
03
Conditions
exudative macular degeneration
Beyond the preview
Go deeper on CTR20255009.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20255009.